Clinical Trials Browser

Completed × Interventional × denileukin diftitox × Clear all

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT01127451 2022-04-13

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

Phase 2 Completed

75 enrolled 15 charts

Dermatologic

Melanoma, Neoplasms

NCT00211185 2020-03-18

A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma

Phase 2 Completed

49 enrolled 11 charts

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT00357448 2019-05-14

Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer

Phase 1 Completed

11 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT00425672 2018-12-05

ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment

Phase 1/2 Completed

15 enrolled 13 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00880360 2018-03-27

ONTAK

Phase 2 Completed

19 enrolled 5 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT00460109 2017-04-18

Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma

Phase 2 Completed

24 enrolled 6 charts

Lymphoid

Lymphoma, Lymphoma, Follicular

NCT00082940 2017-01-19

Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia

Phase 2 Completed

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00228358 2014-11-11

Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine

Phase 1 Completed

8 enrolled

BreastGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT00299689 2014-09-05

Phase II Trial of Ontak With Metastatic Melanoma

Phase 2 Completed

69 enrolled 3 charts

Dermatologic

Melanoma, Neoplasm Metastasis

NCT00082914 2013-06-20

Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer

Phase 2 Completed

DermatologicGenitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma

NCT00006345 2013-05-30

Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma

Phase 2 Completed

DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Drug-Related Side Effects and Adverse Reactions

NCT00138164 2013-05-30

Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 2 Completed

50 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00278369 2013-05-22

Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer

Phase EARLY_PHASE1 Completed

20 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00128622 2012-11-12

Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer

Phase 1 Completed

24 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Breast Neoplasms, Male, Small Cell Lung Carcinoma

NCT00211276 2012-03-14

A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma

Phase 2 Completed

50 enrolled

Lymphoid

Lymphoma, B-Cell

NCT00493129 2012-02-08

Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)

Phase 2 Completed

8 enrolled

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT00055146 2009-04-17

Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)

Phase 2 Completed

41 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00050999 2008-03-05

Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients

Phase 4 Completed

195 enrolled

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00051012 2008-03-05

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

Phase 4 Completed

86 enrolled

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00211198 2008-03-05

Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)

Phase 4 Completed

60 enrolled

DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Clinical Trials

Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma

Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer

ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment

ONTAK

Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma

Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia

Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine

Phase II Trial of Ontak With Metastatic Melanoma

Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer

Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma

Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer

Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer

A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma

Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)

Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)

Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)